136 related articles for article (PubMed ID: 38670300)
1. Uptake of SGLT2i and Outcomes in Patients with Diabetes and Heart Failure: A Population-Based Cohort and a Specialized Clinic Cohort.
Gagnon LR; Hazra D; Perera K; Wang K; Kashyap N; Sadasivan C; Youngson E; Chu L; Dover DC; Kaul P; Simpson S; Bello A; McAlister FA; Oudit GY
Am Heart J; 2024 Aug; 274():11-22. PubMed ID: 38670300
[TBL] [Abstract][Full Text] [Related]
2. Utilization rates and predictors of sodium glucose cotransporter 2 inhibitor use in patients with heart failure with or without type 2 diabetes.
Bermudez SR; Anderson JR; Bos AJ; Ray GM
Am J Health Syst Pharm; 2023 Dec; 80(24):1787-1795. PubMed ID: 37551996
[TBL] [Abstract][Full Text] [Related]
3. Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure.
Chen K; Nie Z; Shi R; Yu D; Wang Q; Shao F; Wu G; Wu Z; Chen T; Li C
JAMA Netw Open; 2023 Aug; 6(8):e2330754. PubMed ID: 37615988
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
[TBL] [Abstract][Full Text] [Related]
5. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
Lytvyn Y; Bjornstad P; Udell JA; Lovshin JA; Cherney DZI
Circulation; 2017 Oct; 136(17):1643-1658. PubMed ID: 29061576
[TBL] [Abstract][Full Text] [Related]
6. Use of sodium-glucose cotransporter 2 inhibitors in Alberta adults with chronic kidney disease: a cross-sectional study identifying care gaps to inform knowledge translation.
Lau D; Pannu N; Yeung RO; Scott-Douglas N; Klarenbach S
CMAJ Open; 2023; 11(1):E101-E109. PubMed ID: 36720493
[TBL] [Abstract][Full Text] [Related]
7. The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study.
Chen HY; Huang JY; Siao WZ; Jong GP
Cardiovasc Diabetol; 2020 Jun; 19(1):73. PubMed ID: 32503541
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D).
Ryan PB; Buse JB; Schuemie MJ; DeFalco F; Yuan Z; Stang PE; Berlin JA; Rosenthal N
Diabetes Obes Metab; 2018 Nov; 20(11):2585-2597. PubMed ID: 29938883
[TBL] [Abstract][Full Text] [Related]
9. Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: a comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society.
Nakai M; Iwanaga Y; Kanaoka K; Sumita Y; Nishioka Y; Myojin T; Kubo S; Okada K; Soeda T; Noda T; Sakata Y; Imamura T; Saito Y; Yasuda S; Miyamoto Y
Cardiovasc Diabetol; 2022 Aug; 21(1):157. PubMed ID: 35964039
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis.
Barbarawi M; Al-Abdouh A; Barbarawi O; Lakshman H; Al Kasasbeh M; Chen K
Heart Fail Rev; 2022 May; 27(3):951-960. PubMed ID: 33620621
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
Fu EL; Patorno E; Everett BM; Vaduganathan M; Solomon SD; Levin R; Schneeweiss S; Desai RJ
Eur Heart J; 2023 Jun; 44(24):2216-2230. PubMed ID: 37259575
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Continuing SGLT2 Inhibitors on Outcomes in Patients with Acute Decompensated Heart Failure.
Nakagaito M; Imamura T; Joho S; Ushijima R; Nakamura M; Kinugawa K
Int Heart J; 2021 Jul; 62(4):885-890. PubMed ID: 34276019
[TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis.
Pandey AK; Dhingra NK; Hibino M; Gupta V; Verma S
ESC Heart Fail; 2022 Apr; 9(2):942-946. PubMed ID: 35112512
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction.
Riaz M; Smith SM; Dietrich EA; Winchester DE; Guo J; Park H
Pharmacotherapy; 2023 Oct; 43(10):1024-1031. PubMed ID: 37459069
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter 2 inhibitors and cardiovascular clinical outcomes in acute heart failure: A narrative review.
Rodriguez R; Kaluzna SD
Am J Health Syst Pharm; 2023 Jun; 80(13):818-826. PubMed ID: 36971375
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose cotransporter-2 inhibitors in heart failure patients across the range of body mass index: a systematic review and meta-analysis of randomized controlled trials.
Adamou A; Chlorogiannis DD; Kyriakoulis IG; Stamatiou I; Koukousaki D; Kardoutsos I; Sagris D; Doehner W; Ntaios G
Intern Emerg Med; 2024 Mar; 19(2):565-573. PubMed ID: 38353880
[TBL] [Abstract][Full Text] [Related]
19. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
[TBL] [Abstract][Full Text] [Related]
20. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Yang S; Zhao L; Mi Y; He W
Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]